Literature DB >> 20386452

Magnetic resonance imaging in spondyloarthritis.

Helena Marzo-Ortega1, Dennis McGonagle, Alexander N Bennett.   

Abstract

PURPOSE OF REVIEW: The study of the early involvement of the axial skeleton has dominated the research map in spondyloarthritides (SpA) in recent months. MRI remains the imaging method of choice to visualize the sacroiliac joint and spine as recognized by the new classification criteria for axial SpA. This review synthesises the most recently published data and offers a critical appraisal of findings. RECENT
FINDINGS: MRI studies of inflammatory back pain of short duration have identified disease starting simultaneously in the lumbar spine and sacroiliac joints in a proportion of patients and confirm MRI as a reliable measure to assess efficacy of biologic agents in early axial SpA. The new Assessment of SpondyloArthritis International Society classification criteria can be applied in the presence and absence of radiographic abnormalities of the sacroiliac joints. Imaging studies of the spine have confirmed the diagnostic utility of spinal MRI in SpA and have described highly specific lesions such as inflammatory vertebral and posterior element lesions or the postinflammatory fatty Romanus lesions.
SUMMARY: MRI in axial SpA is the most rapidly expanding area of translational research in SpA. The publication of the new Assessment of SpondyloArthritis International Society classification criteria for axial SpA heralds a new era for the identification of early disease and mirrors the existing use of MRI in clinical practice for the evaluation of inflammatory back pain.

Entities:  

Mesh:

Year:  2010        PMID: 20386452     DOI: 10.1097/BOR.0b013e328339381e

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  8 in total

1.  Musculoskeletal imaging of the inflammatory and degenerative joints: current status and perspectives.

Authors:  Fausto Salaffi; Marina Carotti; Antonio Barile
Journal:  Radiol Med       Date:  2019-02-27       Impact factor: 3.469

Review 2.  Early axial spondyloarthritis.

Authors:  Robert A Colbert
Journal:  Curr Opin Rheumatol       Date:  2010-09       Impact factor: 5.006

3.  T2-mapping of the sacroiliac joints at 1.5 Tesla: a feasibility and reproducibility study.

Authors:  Domenico Albano; Vito Chianca; Renato Cuocolo; Rodolfo Bignone; Francesco Ciccia; Luca Maria Sconfienza; Massimo Midiri; Arturo Brunetti; Roberto Lagalla; Massimo Galia
Journal:  Skeletal Radiol       Date:  2018-04-20       Impact factor: 2.199

4.  Drug therapy of inflammatory arthritis.

Authors:  Nicola J Gullick; David L Scott
Journal:  Clin Med (Lond)       Date:  2012-08       Impact factor: 2.659

5.  Bone edema of the whole vertebral body: an unusual case of spondyloarthritis.

Authors:  Augusta Ortolan; Paolo Lazzarin; Mariagrazia Lorenzin; Lucia Rampin; Roberta Ramonda
Journal:  Clin Rheumatol       Date:  2016-09-27       Impact factor: 2.980

6.  Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI).

Authors:  Anthony Balducci; Brooke M Helfer; Eric T Ahrens; Charles F O'Hanlon; Amy K Wesa
Journal:  J Inflamm (Lond)       Date:  2012-06-21       Impact factor: 4.981

7.  High bone turnover assessed by 18F-fluoride PET/CT in the spine and sacroiliac joints of patients with ankylosing spondylitis: comparison with inflammatory lesions detected by whole body MRI.

Authors:  Dorothee R Fischer; Christian W A Pfirrmann; Veronika Zubler; Katrin D M Stumpe; Burkhardt Seifert; Klaus Strobel; Giorgio Tamborrini; Gustav K von Schulthess; Beat A Michel; Adrian Ciurea
Journal:  EJNMMI Res       Date:  2012-07-12       Impact factor: 3.138

8.  Pannus inflammation in sacroiliitis following immune pathological injury and radiological structural damage: a study of 193 patients with spondyloarthritis.

Authors:  Dan Min Wang; Ling Lin; Jian Hua Peng; Yao Gong; Zhi Duo Hou; Su Biao Chen; Zheng Yu Xiao
Journal:  Arthritis Res Ther       Date:  2018-06-08       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.